Evidence map›Paper›PMID 28846627›Full record

ArticleMarine drugs2017

Paulomycin G, a New Natural Product with Cytotoxic Activity against Tumor Cell Lines Produced by Deep-Sea Sediment Derived Micromonospora matsumotoense M-412 from the Avilés Canyon in the Cantabrian Sea.

Aida Sarmiento-Vizcaíno, Alfredo F Braña, Ignacio Pérez-Victoria, Jesús Martín, Nuria de Pedro, Mercedes de la Cruz, Caridad Díaz, Francisca Vicente, José L Acuña, Fernando Reyes and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Actinomycetes: A Source of Anticancer Metabolites.Current medicinal chemistry · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Aida Sarmiento-VizcaínoDepartamento de Biología Funcional, Área de Microbiología, and Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain. UO209983@uniovi.es.
Alfredo F BrañaDepartamento de Biología Funcional, Área de Microbiología, and Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain. afb@uniovi.es.
Ignacio Pérez-VictoriaFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda, del Conocimiento 34, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. ignacio.perez-victoria@medinaandalucia.es.
Jesús MartínFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda, del Conocimiento 34, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. jesus.martin@medinaandalucia.es.
Nuria de PedroFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda, del Conocimiento 34, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. ndepedro@lifelength.com.
Mercedes de la CruzFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda, del Conocimiento 34, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. mercedes.delacruz@medinaandalucia.es.
Caridad DíazFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda, del Conocimiento 34, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. caridad.diaz@medinaandalucia.es.
Francisca VicenteFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda, del Conocimiento 34, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. francisca.vicente@medinaandalucia.es.
José L AcuñaDepartamento de Biología de Organismos y Sistemas, Área de Ecología, Universidad de Oviedo, 33006 Oviedo, Spain. acuna@uniovi.es.
Fernando ReyesFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda, del Conocimiento 34, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. fernando.reyes@medinaandalucia.es.
Luis A GarcíaDepartamento de Ingeniería Química y Tecnología del Medio Ambiente, Área de Ingeniería Química, Universidad de Oviedo, 33006 Oviedo, Spain. luisag@uniovi.es.
Gloria BlancoDepartamento de Biología Funcional, Área de Microbiología, and Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain. gbb@uniovi.es.
Fundación Medina · ESUniversidad de Oviedo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present article describes a structurally novel natural product of the paulomycin family, designated as paulomycin G (

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsCarcinoma, HepatocellularCell Line, TumorCyclohexenesDisaccharidesDose-Response Relationship, DrugDrug Screening Assays, AntitumorGeologic SedimentsHep G2 CellsHumansLiver NeoplasmsMarine BiologyMCF-7 CellsMicromonosporaMolecular StructureAnti-Bacterial AgentsAntineoplastic AgentsCyclohexenesDisaccharidespaulomycin GantitumorCantabrian Sea-derived actinobacteriaMicromonosporapaulomycins

Identifiers

PMID28846627
PMCPMC5618410
OpenAlexW2750456116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.